Drug, Device Makers Cheer As FDA Punts Off-Label Policy
Friday’s move marked the third delay of a new FDA policy for assessing the “intended use” of drugs and devices. The concept looks at whether products are intentionally being promoted for unapproved uses, which can lead to criminal misbranding charges or False Claims Act liability.
In a proposed rule on Friday, the FDA said...
To view the full article, register now.